Dr Reddy’s gets 3 observations from USFDA for US-based API plant

We will address them comprehensively within the stipulated timeline. Currently, we do not have any sales from this plant

138
USFDA
Picture: Pixabay

Last Updated on March 11, 2021 by The Health Master

Dr Reddy”s Laboratories on Wednesday said the US health regulator has issued a Form 483 with three observations after inspecting its manufacturing facility in Middleburg, New York.

The audit of the company”s active pharmaceutical ingredients (API) manufacturing plant at Middleburg, New York has been completed by the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a regulatory filing.

“We have been issued a Form 483 with 3 (three) observations. We will address them comprehensively within the stipulated timeline. Currently, we do not have any sales from this plant,” it added.

As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related acts.

Shares of the company on Wednesday ended 1.15 per cent up at Rs 4,498.65 apiece on the BSE.


Also read:

World’s most expensive drug, costs ₹18 crore per dose

NATCO gets USFDA nod for Breast Cancer treatment drug

Kite gets USFDA nod for drug to treat Follicular Lymphoma

Shilpa Medicare gets USFDA tentative nod for drug for Arthritis

Aleor Dermaceuticals gets USFDA nod for Testosterone Gel

Unichem gets USFDA nod for Guanfacine Tablets

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner